Investor Presentation May 2025 1 January 14, 2025 Safe Harbor / Non-GAAP financial measures This presentation contains forward-looking statements within the meaning of the federal securities laws. Statements in this presentation which are not strictly historical statements including, without limitation, express or implied statements or guidance regarding Repligen's financial results for full year 2025, future financial performance and other statements identified by words like "estimated," "anticipated," "gu ...

Core Insights - Absci Corporation has transitioned to a clinical-stage biopharmaceutical company with the initiation of Phase 1 trials for ABS-101, the first AI-designed biologic targeting inflammatory bowel disease (IBD) [1][2][3] Group 1: ABS-101 Development - ABS-101 is an investigational anti-TL1A antibody engineered using Absci's generative AI platform, demonstrating high potency and reduced immunogenicity risk, allowing for quarterly subcutaneous dosing [2][4] - The Phase 1 study is randomized, double-blind, and placebo-controlled, enrolling approximately 40 healthy adult participants to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) [2][3] - Interim safety, PK/PD, and immunogenicity data for ABS-101 are expected in the second half of 2025 [2][4] Group 2: Pipeline and Future Prospects - In addition to ABS-101, Absci is advancing ABS-201, an anti-prolactin receptor antibody for androgenetic alopecia, with Phase 1 trials anticipated to begin in early 2026 [3][6] - The company emphasizes the potential of its generative AI platform to accelerate the development of innovative therapeutics, aiming to bring better biologics to patients more quickly [3][5] Group 3: Company Overview - Absci utilizes an Integrated Drug Creation™ platform that combines AI models with synthetic biology to design therapeutics targeting challenging medical conditions [5][6] - The company is headquartered in Vancouver, WA, with additional facilities in New York City and Switzerland, and collaborates with various pharmaceutical and biotech partners to enhance its therapeutic pipeline [6]